Cargando…
Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells
SIMPLE SUMMARY: The clinical implementation of novel precision medicine strategies in high-grade serous ovarian cancer (HGSOC), the most common and aggressive ovarian cancer subtype, are urgently needed. Targeted immunotherapeutic combinations that maximize drug benefits are of particular interest....
Autores principales: | Gerton, Thomas J., Green, Allen, Campisi, Marco, Chen, Minyue, Gjeci, Iliana, Mahadevan, Navin, Lee, Catherine A. A., Mishra, Ranjan, Vo, Ha V., Haratani, Koji, Li, Ze-Hua, Hasselblatt, Kathleen T., Testino, Bryanna, Connor, Trevor, Lian, Christine G., Elias, Kevin M., Lizotte, Patrick, Ivanova, Elena V., Barbie, David A., Dinulescu, Daniela M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452550/ https://www.ncbi.nlm.nih.gov/pubmed/37627156 http://dx.doi.org/10.3390/cancers15164128 |
Ejemplares similares
-
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023) -
Tumor-Derived cGAMP Regulates Activation of the Vasculature
por: Campisi, Marco, et al.
Publicado: (2020) -
Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies
por: Campisi, Marco, et al.
Publicado: (2022) -
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
por: Yoshida, Ryohei, et al.
Publicado: (2022) -
Molecular characteristics and tumorigenicity of ascites‐derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer
por: Ding, Yi, et al.
Publicado: (2021)